BYLINE BANCORP, INC. (BY): debt financing — Byline Bancorp issues $75M 6.875% sub notes due 2035, redeems $75M 6.00% notes due 2030

BYLINE BANCORP, INC.

Issued $75.0M aggregate principal of 6.875% Fixed-to-Floating Rate Subordinated Notes due 2035.
Net proceeds to redeem $75.0M of outstanding 6.00% Fixed-to-Floating Subordinated Notes due 2030.
Notes qualify as Tier 2 regulatory capital; fixed rate 6.875% until 2030 then floating at 3M SOFR+322bps.
Piper Sandler sole placement agent; notes unregistered private placement.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BYLINE BANCORP, INC. incurred senior notes of $75.0 million in aggregate principal amount with certain institutional accredited investors and qualified institutional buyers at 6.875% Fixed-to-Floating maturing August 15, 2035.

Instrument: senior notes
Principal: $75.0 million in aggregate principal amount
Counterparty: certain institutional accredited investors and qualified institutional buyers
Rate: 6.875% Fixed-to-Floating
Maturity: August 15, 2035
Event: incurrence

Exact text from the filing

On August 7, 2025, Byline Bancorp, Inc. (the “Company”) entered into a Subordinated Note Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors and qualified institutional buyers (the “Purchasers”) pursuant to which the Company sold and issued $75.0 million in aggregate principal amount of its 6.875% Fixed-to-Floating Rate Subordinated Notes due 2035 (the “Notes”).

View on SEC.gov

Browse all debt financings →

BYLINE BANCORP, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-105001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.